Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 14 of 14

List	Outcome	Time frame	Description
Primary	Primary Outcome Measure - Trial I	7 days	Trial I Aqueous Humor CMV Viral Load at Day 7
Primary	Primary Outcome Measure - Trial II	12 months	Trial II Recurrence of Anterior Uveitis Inflammation Over 12 Months
Secondary	Secondary Outcome Measure - Trial I	7 days	Trial I proportion of patients achieving clinical inactivity of anterior chamber inflammation at Day 7
Secondary	Secondary Outcome Measure Trial I at 21 days	21 days	Trial I Clinical proportion of patients achieving clinical inactivity of anterior chamber Inflammation at Day 21
Secondary	Trial I intraocular pressure at 7 days	7 days	Trial I Intraocular Pressure at Day 7
Secondary	Intraocular pressure at 21 days	21 days	Trial I Intraocular Pressure at Day 21
Secondary	Visual acuity at 7 days	7 days	Trial I Visual Acuity at Day 7
Secondary	Visual acuity at 21 days	21 days	Trial I Visual Acuity at Day 21
Secondary	Topical corticosteroid effect on baseline CMV viral load	7 days	Change in aqueous humor CMV viral load (IU/mL) per additional topical corticosteroid drop used daily at the time of first anterior chamber paracentesis
Secondary	Presence of detectable CMV viral load during recurrence in Trial II	12 months	Trial II Presence of Detectable Aqueous CMV Viral Load at Time of Recurrence
Other	Trial topical ganciclovir 2% vs placebo	7 days	Trial I Topical Ganciclovir 2% Versus Placebo: Post-Treatment CMV Viral Load at Day 7 (Subsidiary Analysis)
Other	Prevalence of CMV antiviral resistance mutations in Trial II recurences	12 months	Trial II Prevalence of CMV Mutations Conferring Antiviral Resistance at Time of Recurrence
Other	Host transcriptional profiles	12 months	Specific Aim 3 Host Transcriptional Signatures in CMV Anterior Uveitis (Translational)
Other	Time to first recurrence during Trial II	12 months	Trial II Time to First Recurrence of Inflammation

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07513623/registered

API reference For AI assistants